Related Experiment Videos
Recent advances in the immunologic classification of leukemia
Seminars in Hematology
|October 1, 1986
Summary
Monoclonal antibodies and molecular probes reveal that acute lymphoblastic leukemia (ALL) is diverse. While useful for distinguishing ALL from acute myeloid leukemia (AML), their role in subtyping AML requires further investigation.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Leukocyte differentiation and leukemia origins are studied using cell surface antigens and gene probes.
- Immunoglobulin and T cell receptor genes are identified using molecular probes.
- Established markers include surface/cytoplasmic immunoglobulin (B lymphocytes), sheep erythrocyte receptors (T lymphocytes), and cytochemical stains.
Purpose of the Study:
- To investigate the heterogeneity of acute lymphoblastic leukemia (ALL).
- To assess the utility of monoclonal antibodies in distinguishing acute myeloid leukemia (AML) from ALL.
- To explore the potential prognostic value of surface markers for AML subclassification, moving beyond the French-American-British (FAB) classification.
Main Methods:
- Utilizing monoclonal antibodies to define cell surface antigens.
- Employing molecular probes to identify immunoglobulin and T cell receptor genes.
- Combining these with established markers like B and T lymphocyte surface/cytoplasmic markers and cytochemical stains.
Main Results:
- Studies confirm that acute lymphoblastic leukemia (ALL) is a heterogeneous disease.
- Monoclonal antibodies effectively differentiate acute myeloid leukemia (AML) from ALL.
- The subclassification of AML using monoclonal antibodies shows less certainty compared to ALL.
Conclusions:
- Acute lymphoblastic leukemia (ALL) exhibits significant heterogeneity.
- Monoclonal antibodies are valuable for distinguishing AML from ALL.
- Further research is needed to establish the prognostic utility of differentiation-associated antigens for AML subclassification.